This week on "The Top Line," we'll share highlights from the Cell & Gene Therapy Forum. Lack of access and multimillion-dollar costs have stirred debate over the appropriate price of potentially lifesaving cell and gene therapies. Fierce’s Max Bayer spoke with a panel of stakeholders at the forum. They discussed the state of play for cell and gene therapies and how they can become a genuine game changer for the many, not the few. We also talk with executives from Poseida Therapeutics and AviadoBio. 

To learn more about topics in this episode:

• Zolgensma for dementia? AviadoBio gains orphan tag for one-dose gene therapy 
• Poseida taps former Novartis VP as president of gene therapy 
• Fierce Biotech Summit: Disruptive gene technology is here—and society seems willing to pay for it
• Fierce Biotech Cell & Gene Forum

"The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

See omnystudio.com/listener for privacy information.